KR20050065519A - 알부민-융합 섬모 신경영양 인자 - Google Patents

알부민-융합 섬모 신경영양 인자 Download PDF

Info

Publication number
KR20050065519A
KR20050065519A KR1020057002155A KR20057002155A KR20050065519A KR 20050065519 A KR20050065519 A KR 20050065519A KR 1020057002155 A KR1020057002155 A KR 1020057002155A KR 20057002155 A KR20057002155 A KR 20057002155A KR 20050065519 A KR20050065519 A KR 20050065519A
Authority
KR
South Korea
Prior art keywords
albumin
protein
leu
axokine
biologically active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020057002155A
Other languages
English (en)
Korean (ko)
Inventor
마티아스 저스
토마스 웨이머
한스-피터 하우저
다렐 슬립
Original Assignee
델타 바이오테크놀로지 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 델타 바이오테크놀로지 리미티드 filed Critical 델타 바이오테크놀로지 리미티드
Publication of KR20050065519A publication Critical patent/KR20050065519A/ko
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Obesity (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
KR1020057002155A 2002-08-07 2003-08-06 알부민-융합 섬모 신경영양 인자 Ceased KR20050065519A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40183302P 2002-08-07 2002-08-07
US60/401,833 2002-08-07

Publications (1)

Publication Number Publication Date
KR20050065519A true KR20050065519A (ko) 2005-06-29

Family

ID=31715745

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057002155A Ceased KR20050065519A (ko) 2002-08-07 2003-08-06 알부민-융합 섬모 신경영양 인자

Country Status (6)

Country Link
EP (1) EP1529108A2 (enExample)
JP (2) JP2005534330A (enExample)
KR (1) KR20050065519A (enExample)
AU (1) AU2003271043A1 (enExample)
CA (1) CA2496002A1 (enExample)
WO (1) WO2004015113A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0329681D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Gene expression technique
US9057061B2 (en) 2003-12-23 2015-06-16 Novozymes Biopharma Dk A/S Gene expression technique
GB0329722D0 (en) 2003-12-23 2004-01-28 Delta Biotechnology Ltd Modified plasmid and use thereof
CN102462662A (zh) * 2010-08-16 2012-05-23 重庆富进生物医药有限公司 脂质体包裹重组人睫状神经营养因子

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2719593B1 (fr) * 1994-05-06 1996-05-31 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur préparation et composition pharmaceutique les contenant.
GB9526733D0 (en) * 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
US6926898B2 (en) * 2000-04-12 2005-08-09 Human Genome Sciences, Inc. Albumin fusion proteins
ES2286128T3 (es) * 2000-06-30 2007-12-01 Zymogenetics, Inc. Proteina zcyto21 tipo interferon.

Also Published As

Publication number Publication date
WO2004015113A2 (en) 2004-02-19
JP2005534330A (ja) 2005-11-17
EP1529108A2 (en) 2005-05-11
AU2003271043A1 (en) 2004-02-25
CA2496002A1 (en) 2004-02-19
WO2004015113A3 (en) 2004-05-06
JP2010213707A (ja) 2010-09-30

Similar Documents

Publication Publication Date Title
CN113038964B (zh) 超长效胰岛素-fc融合蛋白及使用方法
JP7270105B2 (ja) インスリン類似体およびその使用方法
CN103649115B (zh) 多肽
KR20230169417A (ko) Gdf15 융합 단백질 및 이의 용도
WO2014165093A2 (en) Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
JP2010535781A (ja) 肥満に対する処置
KR20150124955A (ko) 사람 성장 호르몬 유사체를 사용한 소아 성장 호르몬 결핍증의 치료 방법
TW201934571A (zh) Fgf21變體、融合蛋白及其應用
CN102459348A (zh) 用于将gdnf和bdnf递送至中枢神经系统的融合蛋白
CN113292646B (zh) Glp-1/胰高血糖素双重激动剂融合蛋白
US20080293638A1 (en) Albumin-fused ciliary neurotrophic factor
CN102516393B (zh) 胰岛素模拟肽融合蛋白和突变体及其应用
JP2018535964A (ja) 線維芽細胞増殖因子(fgf)1アナログによるステロイド誘導性高血糖の処置
CN109134664B (zh) 一种经修饰的生长分化因子及其制备方法和应用
WO2018112200A1 (en) Use of fibroblast growth factor 1 (fgf1)-vagus nerve targeting chimeric proteins to treat hyperglycemia
KR20240029769A (ko) 융합단백질 및 이의 응용
CN113105561B (zh) 一种双靶点融合蛋白的制备方法和应用
US20260125444A1 (en) Fusion protein having triple activity and use thereof
JP2010213707A (ja) アルブミン融合繊毛様神経栄養因子
KR20150110677A (ko) N 말단 절단된 인슐린 유사체
CN100535007C (zh) 胰高血糖素样肽的纯化
JP2024507321A (ja) ヒトglp-1ポリペプチド変異体及びその応用
TW201441253A (zh) 具有n端電荷修飾之促胰島素肽衍生物
CN109195983B (zh) 胰岛新生多肽和类似物的缀合物及其方法
CN118620086B (zh) 一种治疗糖尿病的融合蛋白及其应用

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20050204

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20080730

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20091217

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20110531

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20110827

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20110531

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I